Outcomes for assessment of symptomatic and stabilization/disease modifying drugs.
The safety and efficacy of current symptomatic drugs for AD was established using parallel groups taking different doses of active drugs vs placebo over three to twelve months, whereas drugs with potential stabilizing/disease modifying effects are being tested by adding new compounds or placebo to standard symptomatic drugs over 12 to 18 months. Delaying progression to disease milestones may offer additional validity to these studies. It is unclear if biological and neuroimaging markers will add to the clinical evidence.
Gauthier
Serge
S
Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Verdun, Quebec, Canada.
D015415:Biomarkers / Q000032:analysis; D002170:Canada; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D018450:Disease Progression; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D010043:Outcome and Process Assessment, Health Care / Q000592:standards* / Q000639:trends; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D016896:Treatment Outcome
D015415:Biomarkers